1 The primary end point of CKD progression
was a composite of 50% eGFR loss, eGFR less than 10 mL/min/1.
2 The primary outcome was any vascular complication, which
was a composite of access-site bleeding, access-site hematoma
3 The primary efficacy end point
was a composite of adjudicated cardiovascular death, myocardi
4 The primary outcome
was a composite of adverse perinatal outcomes, which included
5 The primary endpoint
was a composite of all-cause death, AVR, and HF hospitalizati
6 The primary end point
was a composite of all-cause death, myocardial infarction, or
7 t (major adverse cardiac or cerebrovascular events [MACCE])
was a composite of all-cause death, nonfatal myocardial infar
8 The primary efficacy outcome
was a composite of asymptomatic proximal deep-vein thrombosis
9 Primary end point
was a composite of cardiac death and nonfatal myocardial infa
10 The primary safety endpoint
was a composite of cardiac death, myocardial infarction, or s
11 The primary end point
was a composite of cardiovascular death, myocardial infarctio
12 The key secondary end point
was a composite of cardiovascular death, myocardial infarctio
13 The primary endpoint
was a composite of cardiovascular death, myocardial infarctio
14 The key secondary endpoint
was a composite of cardiovascular death, myocardial infarctio
15 The primary efficacy end point
was a composite of cardiovascular death, myocardial infarctio
16 utcome (the time to first major cardiovascular event, which
was a composite of cardiovascular death, non-fatal myocardial
17 The primary end point
was a composite of cardiovascular death, nonfatal myocardial
18 The primary outcome
was a composite of cardiovascular disease events.
19 n and the 24-month incidence of new brain infarction, which
was a composite of clinical ischemic stroke or silent brain i
20 The primary outcome
was a composite of death and thrombotic complications (nonfat
21 The primary end point
was a composite of death from any cause or disabling stroke a
22 The primary end point
was a composite of death from any cause, myocardial infarctio
23 The primary end point
was a composite of death from any cause, nonfatal myocardial
24 The primary outcome
was a composite of death from cardiovascular causes, nonfatal
25 The primary outcome
was a composite of death or neurodevelopmental impairment (ND
26 The primary end point
was a composite of death or severe renal failure leading to r
27 The primary efficacy end point
was a composite of death, myocardial infarction, ischemia-dri
28 The primary end point
was a composite of death, stroke, or myocardial infarction du
29 The primary end point
was a composite of death, the need for dialysis, or a persist
30 The primary safety end point
was a composite of freedom from device- and procedure-related
31 The primary outcome
was a composite of long-term CV events or death, which was as
32 The primary outcome
was a composite of major adverse kidney events (persistent re
33 The primary outcome
was a composite of major postoperative respiratory complicati
34 The primary outcome
was a composite of MI and stroke events based on primary disc
35 The primary outcome measure
was a composite of myocardial infarction and target vessel fa
36 The primary endpoint
was a composite of myocardial infarction, stroke, and death f
37 The secondary renal outcome
was a composite of new-onset persistent macroalbuminuria, per
38 The primary outcome
was a composite of nonfatal acute myocardial infarction, nonf
39 Functional impairment
was a composite of poor academic performance (defined as at l
40 The primary outcome of interest
was a composite of postoperative major complications.
41 ed as vessel-oriented clinical end point (VOCE) at 2 years,
was a composite of prospectively adjudicated cardiac death, v
42 The primary efficacy end point
was a composite of recurrent nonfatal ischemic stroke, fatal
43 The primary outcome
was a composite of recurrent venous thromboembolism or major
44 The primary outcome
was a composite of repeat ED visit, hospital admission, or de
45 p1 or placebo (modified intention-to-treat population), and
was a composite of stable or increased lean body mass and sta
46 The primary outcome
was a composite of stent-related complications defined as pai
47 The primary end point
was a composite of survival free of disabling stroke (with di
48 The primary efficacy outcome
was a composite of symptomatic deep-vein thrombosis or pulmon
49 The primary outcome
was a composite of systemic inflammatory response syndrome an
50 The primary outcome
was a composite of treatment failure defined by any of the fo